INDEX

ABSORPTION
buccal, 29
chewing tobacco, 281
cigarette smoke, 29, 281
lung, 29
nicotine polacrilex gum, 281
other tobacco exposure, 29
smoking behavior, 153

ABSTINENCE
(See also CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)
aggression, 203
spontaneous withdrawal assessment, 293
weight gain, relapse predictor, 440
withdrawal syndrome, reinforcement, 197

ACETYLCHOLINE
desynchronization of electroencephalograms, 110
high-affinity binding sites, 90, 92
nicotinic cholinergic agonists, 81
receptor measurement, 53
release in cerebral cortex, 96
turnover in hippocampus and frontal cortex, 98

ADDITION
definitions, 7, 149, 247-248, 249-250, 296
effects of selected drugs, 299-303
identification of hazardous drugs, 304
nicotine and tobacco, 6, 8
perceived functions of smoking, 397
relationship to physical dependence, 296

ADOLESCENTS—Contd.
negative- and positive-affect regulation, smoking, 399
perceptions of stress, 121
smoking prevalence, 573-577
vulnerability factors, 266-267
weight control and smoking, 438

ADVERTISING
increased drug use, 305
low-yield cigarettes, health risks, 566

AGE FACTORS
body weight effects, 415, 416, 418, 424, 431
relapse, 316
smoking cessation, 580-581
smoking prevalence, 569, 579

ALCOHOL
aversive stimuli, 280
discriminative effects, 272
multidrug use, 261-264
place conditioning, 285
prohibition and decreased use, 365
reinforcement, 282

ALCOHOL CONSUMPTION
abuse, smoking as risk factor, 401
body weight, smokers vs. nonsmokers, 417-418, 431
cigarette consumption effects, 167
smoking prevalence among alcoholics, 402

ALKALOIDS, TOBACCO
2,3'-dipyridyl, structure, 27
6-oxoanabasine, structure, 27
anabasine, structure, 27
anabasine, structure, 27, 28
anatabine, structure, 27, 28
metanicotine, structure, 27
myosmine, structure, 27, 28
N'-formyl-nornicotine, content, 28
N'-methylanabasine, structure, 27
N'-methylanatabine, structure, 27
INDEX

ALKALOIDS, TOBACCO—Contd.
N'-nitrosonornicotine, structure, 27
nicotine N'-oxide, structure, 27
nicotyrine, structure, 27
nornicotine, structure, 27, 28
nornicotyrine, structure, 27
pharmacologic effects, 56
pseudooxynicotine, structure, 27

AMPHETAMINES

AMPHEH'AMINES

ANABASINE
content, 28
discrimination, nicotine-trained ani-
mals, 172
respiratory and cardiovascular ef-
fects, 57
structure, 27

ANTAGONISTS
mecamylamine, 494–495
naloxone-precipitated withdrawal
syndrome, 297
nicotine effects in brain, reinforce-
ment, 192
precipitated withdrawal syndrome,
293
pretreatment, smoke intake, 166

ANXIETY
consumption increases, 404
deprivation, 405
neuroticism and adult smoking
habit, 402
pain thresholds, abstinence vs.
high-nicotine cigarettes, 406–407
reduction, affect regulation, smok-
ing, 386, 387
reduction, cognitive appraisal, 411–
412
weight gain, smokers vs. nonsmok-
ers and ex-smokers, 422
withdrawal symptom, 199, 201, 204
withdrawal symptom, with nicotine
polacrilex gum, 208, 210

ARECOLINE
discriminative stimulus, 172, 175
hippocampal theta activity, 109

ATROPINE—Contd.
low dependence potential, 285

AUDITION
amplitude decreases, withdrawal
symptom, 204
auditory evoked response during
smoking abstinence, 202
information task, smoking effects,
385
psychological enhancement and
sensory gratification, 413
vigilance tasks, smoking effects,
393

AUTONOMIC NERVOUS SYSTEM
myenteric plexus, 96
peripheral cholinergic neuron stim-
ulation, 79
phasic increases, emotional stimula-
tion, 411

AVERSIVE THERAPY
contingency contracting, 494–495
coversensitization, 486
directed smoking, 488
less severe techniques, 492–493
rapid smoking, 501
relaxation training, 493–494
unpleasant conditions, 501

BEHAVIOR, ANIMAL
associated stimuli, 309
drug seeking, 309
food intake and body weight, nic-
totine administration, 434
negative-affect-reducing properties
of nicotine, 407
physical activity, nicotine adminis-
tration and cessation, 435
place preference or aversion, 194–
195
reinforcing drug effects, 279
self-administration of drugs, 279

BEHAVIOR, HUMAN
classically conditioned, 307
compulsive use, 250
counseling, 502–503
drug seeking, 310
nicotine self-administration, nega-
tive reinforcement, 193–194
operative, 192

620
INDEX

BEHAVIOR, HUMAN—Contd.
  repetitive and stereotypic drug use, 8
  respondent, 307
  treatment strategies, 487-503
BELGIUM
  body weight, smokers vs. nonsmokers and ex-smokers, 419, 420
BIOASSAYS
  cotinine and nicotine, 42-43
  enzyme-linked immunosorbent assay, 43
  gas chromatography, 43
  mass spectrometry, 43
  radioimmunoassay, 43
BIOCHEMICAL MARKERS
  blood cotinine, 38, 42
  blood nicotine, 42
  carboxyhemoglobin, 42, 514
  cotinine, 515
  metabolism of nicotine, 41
  salivary cotinine levels, 42
  thiocyanate, 514-515
  urinary cotinine levels, 42
BLACK AMERICANS
  (See also ETHNIC GROUPS)
  cessation motivation and success, 510
  cessation of smoking, 508-509
  church and fraternal roles, 511-512
  coronary risk trial, 511
  health care access, 509
  physician influence, 511
  quit-smoking treatments, 511-512
  smoking and quitting patterns, 510
  social norms and advertising, 509-510
  sociodemographic factors, 509
BLOCKADE THERAPY
  mecamylamine, 484-485
  opioid dependence, 484
  tobacco dependence, 484-485
BLOOD
  carboxyhemoglobin, 39
  cotinine, 36
  nicotine, 30-33, 38-39
  pH and nicotine measures, 41
  wound healing, 600
BLOOD PRESSURE
  changes during abstinence or relapse, 202, 205
  hypertension relationship to smoking, 600-601
  stress and nicotine, 409
BODY HEIGHT
  smokers vs. nonsmokers and ex-smokers, 416, 418
BODY TEMPERATURE
  changes, withdrawal symptom, 202
  skin, changes during abstinence or relapse, 202, 205
BODY WEIGHT
  adipose tissue, relative nicotine level, 39
  carbohydrate metabolism and smoking, 107
  changes during abstinence or relapse, 205
  control, smoking and nicotine effects, 381
  gains after nicotine cessation, animals, 432
  hypothalamic consummatory drive model, nicotine, 412-413
  nicotine administration, animals, with food intake, 434
  nicotine polacrilex gum, effects, 432
  smokers vs. nonsmokers and ex-smokers, 414-441
  smoking cessation effects, 199, 202, 439
  weight loss and nicotine, animals, 432
BRAIN
  alpha, beta, and theta power, with smoking, 111-112
  anteroventral thalamic nucleus, 86, 94
  blood-brain barrier, nicotine isometheonium penetration, 57
  caudate nucleus, 94
  central grey matter, 86-87
  cerebellum, 94
  cerebral cortex, 94
  chemical mediation of nicotine, 8
  cortical arousal, withdrawal symptom, 202, 204
  cortical electric potentials, withdrawal symptom, 206
  cortical evoked potentials, withdrawal symptoms with nicotine polacrilex gum, 208
INDEX

BRAIN—Contd.
dentate gyrus, 94

electrocortical effects of nicotine, 107-112

expectancy and orienting waves, 115

frontoparietal cortex, 86-87

glucose utilization, nicotine stimulation, 81, 86-88

hippocampus, 94, 99-100, 109

homovanillic acid levels after nicotine exposure, 110

hypothalamus, 94, 97

interanteromedial thalamic nucleus, 86

interpeduncular nucleus, 86, 94, 95

interpeduncular nucleus and medial habenula, "H-labeled nicotine, 81

lateral geniculate body, 86

lateral habenulae, 86

lateralized affective processors model, stressful conditions, 412

locus coeruleus, 95

medial habenulae, 86, 94, 95

metabolism, binding sites, 85-86

nerve cells, nicotine concentrations, 85

nicotine concentrations, animals, 82-85

nicotine levels, discrimination stimulus, 174

nicotine polacrilex gum, 111-112

nicotine-induced desynchronization, 109

physiological effects of nicotine injections, 96-97

presubiculum, 94

putamen, 94

rapid nicotine uptake, 32-33

rat cerebellum, nicotine effects, 92-93

relative nicotine level, 32

retrosplenial cortex, 86

substantia nigra pars compacta, 94

superior colliculus, 86, 94

ventral tegmental area, 86-88, 94

BUNGAROTOXIN—Contd.

binding sites, 47

binding studies, mammalian brain, 91-94

nicotinic cholinergic receptors, 88-89

CAFFEINE

cigarette consumption effects, 167

nonreinforcer, 281

CANADA

body weight, smokers vs. nonsmokers and ex-smokers, 417

CARBON MONOXIDE

carbon monoxide exposure, 59

concentration, 39

CARCINOGENESIS

benz[a]pyrene-tetradecanoyl phorbol acetate, 604

bladder, 604

respiratory tract, 604

tobacco cigarettes vs. nicotine polacrilex gum, 215

CARDIOVASCULAR SYSTEM

(See also CORONARY HEART DISEASE)

acute tolerance, 48, 49

atherosclerosis, 596-598

body weight, smokers vs. nonsmokers and ex-smokers, 417, 422, 427

carbon monoxide effects, 596

cardiomyopathy, 590-600

contribution of nicotine, 56

coronary artery disease, 598

low-density lipoproteins, 596

nicotine and carbon monoxide, 116-117

nicotine effects, 596-601

stress and smoking, 118

Surgeon General’s Report, 12

thrombosis, 597-598

very low-density lipoproteins, 596

CATECHOLAMINES

amniotic fluid, 603

nicotine effects on central neurons, 100

release from extra-adrenal chromaffin tissues, 97-98

BUNGAROTOXIN

receptor measurement, 53
INDEX

CELLS
nerve, nicotine concentrations, 85

CENTRAL NERVOUS SYSTEM
nicotine concentrations, 83-84
nicotine isomethonium, 57
nicotinic cholinergic receptors, 89
pre- or postsynaptic release of acetylcholine, 95
psychoactive drugs, 267
tranquilization effects of nicotine, 409

CESSATION OF SMOKING
(See also ABSTINENCE; DEPRIVA-
TION; WITHDRAWAL SYMP-
TOMS; WITHDRAWAL SYN-
DROME)
blacks vs. whites, 572
criteria, 516
heavy vs. light smokers, success rates, 577
males vs. females, 580, 581
measurements, 576, 580
men, neuroticism, 402
physical activity changes, 435
program development, nicotine addiction, 6
quit attempts, 150
quit difficulty and daily consumption, 206
quit ratios by age and sex, 1965 to 1985, 581
release and psychophysiological re-
activity, 120
spontaneous remission, 255-259
stages, 518
Surgeon General’s Report, 12
trials, 488-490
weight gain, 414, 416, 422, 423,
424, 425, 431, 439-440

CESSATION OF SMOKING,
METHODS—Contd.
similarity to methods for other
drugs, 467
stimulus control, 497

CHEMICAL DETECTION
biological samples, 256, 259
interpretation, 259
sensitivity, 259
specificity, 259

CHEMICAL STRUCTURE
nicotine, 27
nicotine metabolites, 35
tobacco alkaloids, minor, 27

CHEWING TOBACCO
nicotine absorption, 29, 31
nicotine levels, 38

CHILDREN
negative- and positive-affect regulation,
smoking, 399
smoking and body weight beliefs, 433

CHOLINERGIC AGENTS
acetylcholine release, 81
interaction with biogenic amine
pathways, 98
nicotine effects on central and pe-
ripheral nervous systems, 96-97

CIGAR SMOKING
body weight, smokers vs. nonsmok-
ers, 417, 419
nicotine levels, 38
prevalence, men, 1964 to 1986, 580,
582
Surgeon General’s Report, 12

CIGARETTES, HIGH-NICOTINE
affect modulation, 405
blood nicotine levels, 39
brand loyalty, 567
carboxyhemoglobin levels, 39
effects on recall, 389
emphysema, 604
knee-jerk reflex, 45
visual information processing task,
smoking effects, 384
yields of nicotine, 26

CIGARETTES, HIGH-TAR
brand loyalty, 567
visual information processing task,
smoking effects, 384
INDEX

CIGARETTES, HIGH-YIELD
- carbon monoxide, 59
- heart rate, partial tolerance, 55-56
- smoking behavior, 163

CIGARETTES, LOW-NICOTINE
- affect modulation, 405
- effects on recall, 389
- emphysema, 604
- knee-jerk reflex, 45
- Surgeon General's Report, 12
- visual information processing task, smoking effects, 384

CIGARETTES, LOW-TAR
- Surgeon General's Report, 12
- visual information processing task, smoking effects, 384

CIGARETTES, LOW-YIELD
- carbon monoxide, 59
- consumption, health risks, 566
- heart rate, partial tolerance, 55-56
- vented, smoke concentration, 159-161

COCAINE
- cost, 283-284
- crack, 281
- increase in use, 305-306
- multidrug use, 261-264
- place conditioning, 255
- starter drug, 278

COFFEE CONSUMPTION
- smokers vs. nonsmokers, 437

COGNITION
- concentration difficulty, withdrawal symptom, 199, 201, 204, 205, 208, 310
- euphoria and dysphoria, 117
- oral contraceptive use, response to stress, 118-119
- stressor response among women, 118
- task performance, 394

CONDITIONING
- behavioral tolerance, 259
- cues to smoke, 465
- drug use as learned behavior, 307-309
- drug-opposite response, 289
- nicotine addiction, 460
- pharmacologic and psychological factors, 465
- physiological reactions, 466

CONDITIONING—Contd.
- place preference and aversion, 194, 284
- placebo effects, 309
- taste aversion, 194

CONSUMPTION
- adolescents, 260
- adolescents, stress factor, 400
- adults, effects of stress, 401
- body weight effects, 415, 416, 417, 419, 420, 423, 426, 431
- children, smoking and body weight beliefs, 438
- frequency and multiple drugs, 263-264
- heavy smokers, stress, 403
- heavy vs. light smokers, smoking cessation success, 577
- high-yield cigarettes, 163
- multiple drugs, 260
- occasional tobacco use, 253-254
- prediction, 262-263
- progression of drug use, 261-263
- race, age, and gender factors, 579
- severity of withdrawal symptoms, 206
- United States, 1973 to 1987, 567
- United States, estimation through taxes, 560
- United States, per capita decline, 565-566

CONTROLLED SMOKING
- compensatory behavior, 499-500
- outcomes, 499-500
- parameters, 499
- prospects for abstinence, 500

COPING STRATEGIES
- cognitive versus behavioral techniques, 530-531
- retrospective bias, 531
- self-punititive cognitions, 531
- short and long term effects, 496
- skill-based treatment, 532
- skills training, 496
- stimulus control, 530-531
- stress and smoking habit, 402
- willpower, 531

CORONARY HEART DISEASE
(See also Cardiovascular System)
- ischemia, mortality
- myocardial infarct, 598-599
INDEX

CORONARY HEART DISEASE—Contd.
  myocardial infarct, weight gain after smoking cessation or continuation, 426
  pharmacodynamic aspects, nicotine, 56
  risk, 598
  stress and smoking, 118
  Surgeon General's Report, 11

CORTICOSTEROIDS
  corticosterone and tolerance, 52
  plasma corticosterone levels, 100-101, 103
  plasma levels and cigarette smoking, 104-106

COST
  alternate nicotine delivery systems, 214
  individual and social, 252
  positive and negative incentives, 284
  required work, 283-284
  time, 283

COTININE
  bioassay comparison, 38-40
  biochemical detection, 515
  blood levels with nicotine polacrilex gum, withdrawal symptoms, 209
  content, 28
  daily cigarette consumption, 160
  discrimination, nicotine-trained animals, 172
  levels and severity of withdrawal symptoms, 206-207
  metabolites, 34
  nicotine metabolite, 34-36
  structure, 27
  tobacco-use marker, 38, 40

CRAVING—Contd.
  sensory stimuli, 211
  smokeless tobacco withdrawal symptom, 207
  withdrawal symptom, 199, 201, 204

CYTISINE
  discrimination, nicotine-trained animals, 172-173
  respiratory and cardiovascular effects, 57

DEMOGRAPHIC FACTORS
  (See also SOCIOECONOMIC FACTORS)
  cigarettes and smokeless tobacco, 306
  marital status, 571
  smoking prevalence, 569, 571
  women and youth, 306

DENMARK
  body weight, smokers vs. non-smokers and ex-smokers, 418

DEPENDENCE
  aversive limits, 268
  behavioral effects, 286
  cross-tolerance, 292
  definitions, 7, 198, 247-248, 245-250
  drug use, 12
  interoceptive drug effects, 268
  levels, 253
  neuroadaptation, 286
  physiological effects, 286
  positive reinforcement, 268
  potential testing, 269-270, 285-286
  progression, 253
  unconditioned stimuli, 268

DEPRESSION
  Navy men, cigarette consumption, 404
  nicotine polacrilex gum, 208-210
  withdrawal symptom, 201

DEPRIVATION
  (See also ABSTINENCE; CESSATION OF SMOKING; WITHDRAWAL SYMPTOMS; WITHDRAWAL SYNDROME)
  attention span of smokers, 386
  effects on memory, 388
  negative affect, 405, 406
  smoking rates and behavior, 164
  stress, relapse, 402
INDEX

DIAZEPAM
- nicotine-induced antagonism, 175
- withdrawal syndrome, 297

DIET
- alkaline, smoking behavior, 163-164
- changes during abstinence or relapse, 205, 206, 433-434
- changes, smokeless tobacco withdrawal symptom, 207
- food intake and appetite, withdrawal symptom, 209
- food intake and smoking-related energy imbalance, 434
- hunger, hypothalamic consummatory drive model, nicotine, 412-413
- hunger, withdrawal symptom with nicotine polacrilex gum, 209, 210
- sweet food intake and weight gain after smoking cessation, 433-434

DISCRIMINATION
- behavior, 274
- drug similarity, 274
- generalization, 274
- intravenous nicotine administration, humans, 176-177
- metrazol, animals, 175
- nicotine, administration method, animals, 171-172
- nicotine, humans, 176-177
- nicotine, pentolinium pretreatment, 176-177
- nicotine vs. 3-methyl-pyridylpyrroldine, 173
- specificity, 275-276
- testing, 274-277

DIZZINESS
- acute sensitivity, 45, 47
- tobacco poisoning, 595

DOPAMINE
- control over acetylcholine turnover, 98
- cue properties of nicotine, 98
- nicotine agonists, 54
- stimulation by nicotine, 54
- turnover and release, 100-101

DOSE CONTROL—Contd.
- ventilated cigarette holders, 159

DOSE-RESPONSE
- amphetamines, 282
- aversive limits, 282
- biphasic effects, 44
- compensatory nicotine intake, 283
- heart rate changes, 56
- psychoactivity, 272
- self-administration and reinforcement, 282
- self-reported effects, 274
- titration-studies, nicotine, 282-283
- tobacco smoke, 282
- withdrawal reactions, 293

DRUG ABUSE
- adolescents, smoking as risk factor, 400-401
- liability factors, 304

DYSPHORIA
- nicotine dose increases, 178

EDUCATION
- high school dropouts, smoking prevalence, 574
- smoking prevalence, 1985, 571

ELECTROENCEPHALOGRAPHY
- activating effects of nicotine, 81-82
- activity in rats, 52
- changes during abstinence or relapse, 205, 206
- distinct central nervous system effects, 108-109
- history of nicotine studies, 108-109
- nicotine-induced desynchronization, 112
- parallels with self-reports, 274
- power spectral analysis, 110
- withdrawal symptoms with nicotine polacrilex gum, 208

ELIMINATION
- acid loading, 40-41
- alkaline loading, 40-41
- kinetics, 38
- measurement of smoke intake, 152
- renal nicotine, 40-41
- tolerance measure, 289
- urinary tract, 33, 34, 36, 37

EMPHYSEMA
- Surgeon General's Report, 11
- weight gain, smokers vs. nonsmokers, 426
INDEX

ENDOCRINE
adrenal cortex, 104-106
follicle-stimulating hormone, 100-102
growth hormone, 101
luteinizing hormone, 100-102
nicotine effects, 96
prolactin, 100-102
thyroid, 104
thyroid-stimulating hormone, 100-102

ENVIRONMENTAL FACTORS
conditioned responses, 306
contingent reinforcement, 306
drug costs, 306
economic factors, 266
individual reactions, 529
negative affect, 530
other smokers, 529-530
parental drug use, 266
peer smoking, 526
place conditioning, 284-285
relationship to direct drug effects, 306, 309
smoking cues, 526, 529-530
spousal smoking, 526-527
stimulus control, 497
stress, 530
withdrawal effects, 204, 310-311

EPINEPHRINE
levels during abstinence or relapse, 204, 205
serum concentrations, 97

ETHNIC GROUPS—Contd.
Oriental aversion to alcohol, 290

EX-SMOKERS
body weight, vs. smokers and nonsmokers, 416-430
spontaneous remission, 466
withdrawal symptoms, 199-200

EYES
nicotine concentrations, 83
pupil enlargement after nicotine use, 274
pupillary constriction from opioids, 291
visual evoked response during smoking abstinence, 202

FINLAND
body weight, smokers vs. nonsmokers and ex-smokers, 429

FRANCE
body weight, smokers vs. nonsmokers and ex-smokers, 422

GANGLIA
localization of nicotine, animals, 85
peripheral cholinergic neuron stimulation, 79

GASTROINTESTINAL SYSTEM
heartburn, 607
peptic ulcer, 605-607
relative nicotine level, 32
small bowel, nicotine reabsorption, 33
stomach, nicotine concentrations, 82-83

GENETIC PREDISPOSITION
adolescent drug use, 266-267
vulnerability factors, 266

HAIR
nicotine recovery, 33

HEADACHE
acute sensitivity, 45, 47
tobacco poisoning, 595

HEART
acute nicotine tolerance, 48, 49
aristolochia, 599
nicotine concentrations, animals, 84

HEART RATE
abstinence or relapse, 122-123, 202, 204, 205, 206
HEART RATE—Contd.
  acute tolerance, 48, 49
  drug and environmental effects, 308
  nicotine-induced tachycardia, 291
  smokeless tobacco withdrawal symptom, 207
  stress and nicotine, 409
  stress and smoking, 118
  tachycardia, 292-493
  withdrawal symptom, 199, 201
  withdrawal symptom with nicotine polacrilex gum, 210

HEROIN
  cigarette consumption effects, 167
  methadone effect, 288

HEXAMETHONIUM
  acetylcholine release blocked, 81
  attenuated amine release, 98
  discrimination, nicotine-trained animals, 174
  inhibiting effects on nicotine, 88, 92-93
  smoke-induced edema, 179

HISPANIC AMERICANS
  (See also ETHNIC GROUPS)
  gender difference, 512
  physician influence, 513
  prevalence of smoking, 512
  smoking cessation, 512-513
  smoking correlates, 512-513

HISTORICAL PERSPECTIVE
  addictive behavior, 269
  discovery of nicotine, 10
  medicinal vs. harmful effects, 9-10
  nicotine addiction, 10-11
  nicotine pharmacology, 10-11
  tobacco use, 9

HORMONES
  adrenocorticotropic, acetylcholine effects, 97
  adrenocorticotropic, nicotine effects, 100-103, 105-106
  androgen, testosterone levels, and smoking, 106
  arginine vasopressin, nicotine-induced release, 102-103
  estrogen production and metabolism, smoking effects, 106
  pro-opiomelanocortin, acetylcholine effects, 97

HORMONES—Contd.
  pro-opiomelanocortin, factors influencing release, 103-104
  prolactin, luteinizing, and follicle stimulating, 52

HYPOTHALAMUS
  consummatory drive model, nicotine, 412-413
  neuroendocrine function, 52

HYPOXEMIA
  fetal development, 603
  subsequent behavioral abnormalities, 603

IMPATIENCE
  nicotine polacrilex gum, 210
  withdrawal symptom, 199, 201

INHALATION PARAMETERS
  measurement techniques, 152
  published values, 156-157

INITIATION
  aversive reactions, 264-265
  dependence, cigarettes vs. nicotine polacrilex gum, 215
  drug classes, 259, 261-265
  environmental motivations, 278
  experimental use, 265
  smokeless tobacco, 265, 584
  social and pharmacologic factors, 264-265
  stress and early smoking onset, 399
  Surgeon General’s Report, 12
  weight control and smoking, 408
  women, neuroticism, 402

INTEROCEPTIVE EFFECTS
  definition, 170
  dependence potential testing, 270-271
  mood and feeling, 270
  morning withdrawal cues, 308-309
  perception, smoke and nicotine, 179
  subjective pleasure, 308
  taste, airway irritation, 179

IRRITABILITY
  changes during abstinence or relapse, 205, 206
  nicotine polacrilex gum, 208, 210
  withdrawal symptom, 199, 201

JAPAN
  body weight, smokers vs. non-smokers and ex-smokers, 420
INDEX

KIDNEYS
nicotine concentrations, 82-84
nicotine elimination, 33, 37
relative nicotine level, 32

LEARNING
behavioral tolerance, 289
letter-digit substitution task, smoking effects, 386-387
nicotine and smoking effects, humans and animals, 386
paired-associated, smoking effects, 387, 388
serial, retention, smoking effects, 388
state-dependent, definition, 389
verbal rote, smoking effects, 387-388

MAINTENANCE OF SMOKING—Contd.
weight control, 438

MARIJUANA SMOKING
cigarette consumption effects, 106
multidrug use, 261-264
smoking as risk factor, 401

MECAMYLAMINE
brain and spinal cord effects, 89
discrimination, nicotine-trained animals, 173-174
dose-response, 93
effects on desynchronization, 109
local cerebral glucose utilization, 86-88
nicotine conditioning taste aversion, 196
nicotine-induced antagonism, 175
nicotinic receptors blocked, 81
pretreatment, effect on conditioned reinforcer, 191
pretreatment, harshness ratings of smoke, 179
pretreatment, negative nicotine reinforcement, 193
pretreatment, nicotine discrimination, 178-179
pretreatment, nicotine polacrilex gum, discrimination, 178
pretreatment, smoke intake, 166

MEMORY
(See also RECALL)
delayed, smoking effects, 388
immediate, smoking effects, 388
nicotine and smoking effects, humans and animals, 386
recognition study, state-dependent, 390
task performance, 394
verbal, smoking and nicotine effects, 399
words and order, smoking effects, 389

METABOLISM
(See also PHYSICAL ACTIVITY)
animal, body weight, smoke exposure or nicotine administration, 436
body weight and smoking, 434, 435-437

LIVER
drug detoxification and tolerance, 290
nicotine concentrations, 82-84
nicotine metabolism, 37
relative nicotine level, 32

LOBELINE
discrimination, nicotine-trained animals, 173
respiratory and cardiovascular effects, 57

LOCOMOTOR ACTIVITY
decreases with nicotine, 49, 51
nicotine induced, 53

LUNG DISEASES
bronchoconstriction, 604
cancer, Surgeon General's Report, 11
chronic bronchial wall inflammation, 603
emphysema, 603
nicotine toxicity, 603-604
pulmonary epithelial permeability, 604
Surgeon General's Report, 12

LUNGS
afferent neuron stimulation, 116
nicotine concentrations, animals, 84
relative nicotine level, 32

LYSERIC ACID DIETHYLAMIDE
(LSD)
nonreinforcer, 281, 282, 285

MAINTENANCE OF SMOKING
Surgeon General's Report, 12

MECA
INDEX

METABOLISM—Contd.
decreased, withdrawal symptom, 203
nicotine clearance, 40
nicotine metabolites, 34, 35, 36
rate, 37
smokers vs. nonsmokers, 53
smoking cessation effects, 433, 436

METHADONE
cigarette consumption effects, 167
effect on heroin use, 288
efficacy, 296

MOOD
changes during abstinence or relapse, 205–206
hedonic systems model, negative affect, 411
regulation, smoking and drug use, 401
regulation, subjective well-being, smoking effects, 394–399

MORPHINE
discrimination, 275–276
euphoria and self-administration, 277
physical dependence, withdrawal, 294
place conditioning, 285

MOTIVATION
behavioral tolerance, 289
gender differences, 506
self-perceived reasons for smoking, 398
treatment enhancement, 332–334

MOTOR BEHAVIOR
alcohol-induced muscle relaxation, 291
smoking and nicotine effects, 392–393
task performance, 394

MUCOUS MEMBRANES
cardiovascular effects of nicotine, 598

MUSCLES
alcohol-induced relaxation, 291
N-methylnicotinium ion, pressor and neuromuscular effects, 57
relative nicotine level, 32
tonic and phasic muscular activity, nicotine effects, 410

MUTAGENESIS
Salmonella typhimurium assays, 605

NALOXONE
cigarette consumption effects, 166
opioid withdrawal, 297

NAUSEA
acute sensitivity, 45, 47
tobacco poisoning, 595

THE NETHERLANDS
body weight, smokers vs. nonsmokers and ex-smokers, 430

NEUROENDOCRINE FUNCTION
nicotine effects, 95–96

NEW YORK
smokeless tobacco use, 1986, 581

NEW ZEALAND
body weight, smokers vs. nonsmokers and ex-smokers, 421

NICOTINE
content, different tobaccos, 28
intake, 40
place conditioning, 285
sensitivity, 40–47
structure, 27

NICOTINE AEROSOLS
respiratory sensations, plasma nicotine levels, 179–180
tobacco-like sensations, cessation method, 180

NICOTINE CONTENT
-cigarettes vs. chewing tobacco, snuff, 28
-high yield cigarettes, 26
-low yield cigarettes, 26

NICOTINE DELIVERY, ALTERNATE
(See also CESSATION OF SMOKING, METHODS; NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT; TREATMENT)
chewable product, FDA ruling, 212–213
dependence potential, 214
nicotine polacrilex gum, dependence and withdrawal, 207–208
potential for abuse with concurrent tobacco use, 213–214
tobacco cigarettes vs. nicotine polacrilex gum, 215
INDEX

NICOTINE DELIVERY, ALTERNATE—Contd.
tolerance, physical dependence, withdrawal symptom alleviation, 212
toothpaste-like formulation, FDA review, 212
toxic effects, convenience, dependence potential, 213

NICOTINE FADING
combination with self-monitoring, 498
definition, 497
low-tar and -nicotine brands, 497–498
outcomes, 498–499

NICOTINE METABOLISM
nicotine-1'-N-oxide, 36
pathways, 34–37
tachyphylaxis, 50

NICOTINE PHARMACOLOGY
addictive properties, 6
discrimination effects, 272
pharmacokinetics, 25, 32
stimulant and depressant effects, 79
tobacco cigarettes vs. nicotine polacrilex gum, 216

NICOTINE POLACRILEX GUM
(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE REPLACEMENT; TREATMENT)
absorption, 29, 31
affect modulation, 405
blood levels of nicotine, 472
body weight effects, 432
combined with behavioral therapy, 476
coronary heart disease, 599
craving reduction, 475
dose–patient relationship, 478–479
duration of use, 478
efficacy trials, 473–474, 476–478
fetal development, 602–603
followup, 477
mood regulation during smoking cessation, 406
physical dependence, 210
physician trials, 476–477
poststimulus components, 115
pretreatment, smoking behavior, 165
relapse, 477–478
safety vs. cigarettes, 214–215
stimulus effects, 178
temporary treatment aid, 214
toxicity, 213
weight gain, 423
withdrawal symptom alleviation, 207, 208, 472

NICOTINE REPLACEMENT
(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; TREATMENT)
adoption treatment, 7
aerosols, 480
comparisons of preparations, 480–481
dependency, 481
forms and rationales, 471
nasal solutions, 479
polacrilex gum, 471–479
side effects, 480
transdermal patches, 479–480

NITROSAMINES
American snuff, 605
chemical structure, 606
mainstream tobacco smoke, 605

NOREPINEPHRINE
levels during abstinence or relapse, 205
neuroendocrine activity, 101
nicotine effects, 100–101
release in hypothalamus, 97

NORNICOTINE
content, 28
discrimination, nicotine-trained animals, 172
structure, 27

NORWAY
body weight, smokers vs. nonsmokers and ex-smokers, 417, 418, 421, 426

OCCUPATIONS
asbestos workers, 422
civil servants, 422
factory workers, 419
farm workers, 594
INDEX

OCCUPATIONS—Contd.
government workers, 418
insurance company employees, 416
manufacturing company employees, 419
nurses, 439
physicians, 438
steel workers, 419
telephone company employees, 420, 423

OPIOIDS
addiction, 247
addictive patterns, 282
chipping, 253
discriminative effects, 272
fetal syndrome, 251-252
physical dependence potential, 286-287
protracted withdrawal, 250
tolerance, 287
withdrawal, 291-294

OXOTREMORINE
discrimination, nicotine-trained animals, 172
muscarinic cholinergic agonist, 52

PANCREAS
body weight and smoking, 107

PASSIVE SMOKING
Surgeon General’s Report, 12

PEER GROUPS
relapse, 321-322
treatment, 334

PENTOBARBITAL
depressant, cigarette consumption effects, 167
discrimination, 275-276

PERFORMANCE
impairment, withdrawal symptom, 204, 205, 206
nicotine polacrilex gum, 203, 208
problem solving, attention, and memory, 391

PERIPHERAL EFFECTS OF NICOTINE
discriminative stimulus, 173
overview, 79

PHARMACODYNAMICS
cardiovascular changes, 55-56
daily smoking patterns, 55
definition, 25
dose-response, 44

PHARMACODYNAMICS—Contd.
tolerance, 44-46

PHARMACOLOGIC TREATMENT
alprazolam, 482
blockade therapy, 328
clonidine, 328-329, 482-483
deterrents, 329
drug replacement therapy, 326-328
mood changes, 483-484
relief from withdrawal symptoms, 327
symptomatic treatment, 328, 481-483

PHYSICAL ACTIVITY
(See also METABOLISM)
body weight differences, smokers vs. nonsmokers, 434
body weight, smoking cessation, 435
decreased energy expenditure, withdrawal symptom, 203
exercise tolerance, 600
smokers vs. nonsmokers, 435

PIPE SMOKING
body weight, smokers vs. nonsmokers, 417, 419
coronary heart disease, 598
nicotine levels, 38
prevalence, men, 1964 to 1986, 580, 582
Surgeon General’s Report, 12

POLAND
body weight, smokers vs. nonsmokers and ex-smokers, 420

POLYDRUG DEPENDENCE
adolescents, 259-260
frequency of use, 263-264
initiation of cigarette and other drug use, 259-260
prediction, 262-263
preference tests, 272-273
progression of use, 261-263
tobacco-opioids-alcohol-stimulants, 254

POTENTIALS, SENSORY EVENT-RELATED
auditory function and nicotine, 112-113
contingent negative variation, 114-115
INDEX

POTENTIALS, SENSORY EVENT-RELATED—Contd.
visual function and nicotine, 113-114

PREGNANCY
amniotic fluid, nicotine recovery, 33
body weight, smokers vs. nonsmokers, 416, 418, 424, 426, 429
breast-milk fluid, nicotine levels, 33
low birth weight, 602
nicotine effects on animals, 602
perinatal mortality, 602
placenta, carbon monoxide and nicotine, 602
placenta, nicotine penetration, 33
prematurity, 602
spontaneous abortion, 602

PRETREATMENT
lidocaine, airway sensations, 169
nicotine, smoking behavior, 165-166
pentolinium, nicotine discrimination, 176-177
pimozide, taste aversion, 196

PREVENTION OF SMOKING
aversive smoking, 501-502
program development, nicotine addiction, 6
skills training, 501

PSEUDOXYNICOTINE
structure, 27

PSYCHIATRIC DISORDERS
multiple diagnosis, 254
negative affect of smoking, 493
neuroticism, 401-402
tobacco-nicotine dependence and withdrawal, 12

PSYCHOACTIVITY
drug classification, 269-270
interoceptive effects, 270
mood and feeling, 270-271
tobacco cigarettes vs. nicotine polacrilex gum, 215

PSYCHOMOTOR PERFORMANCE
letter crossing tests, smoking effects, 384
smoking abstinence vs. nicotine polacrilex gum, 203
smoking and nicotine effects, 381
smoking effects, methodological limitations, 382

PSYCHOMOTOR PERFORMANCE—Contd.
Stroop test, nicotine effects, 385-386
sustained attention tasks, definition, 382

PUFFING PARAMETERS
definitions, 153
frequency, duration, volume, interpuff interval, 153-154
interdependent relationships among measures, 153
measurement techniques, 151-152
published values, 156-157
visual information processing, smoking effects, 384
withincigarette changes, nicotine dose, 155-158

RAPID SMOKING
aversive smoking cessation therapy, 196-197
cardiovascular and pulmonary risks, 493
cumparison with other techniques, 492-493
conditioned aversive response, 492
rapid puffing, 501-503
single and multicomponent procedures, 491-492
stress, 494
tachycardia, 492-493

REACTION TIME
simple and complex, smoking effects, 392-393
smoking abstinence vs. nicotine polacrilex gum, 203
visual and auditory, smoking effects, 385
visual information processing, smoking effects, 384
visual, smoking effects, 383

RECALL
(See also MEMORY)
immediate, nicotine effects, 388
short- and long-term, nicotine tablets, 390
state-dependent, smoking vs. no-smoking conditions, 390
verbal rote learning, smoking effects, 387-388

RECEPTORS
adaptation to drug, 289
binding sites, minor alkaloids, 56
INDEX

RECEPTORS—Contd.
  constitutional tolerance, 290
dihydro-beta-erythroidine, rat brain, 91
disulfoton, 3H-nicotine binding, 54
  functional or pharmacodynamic tolerance, 289

RECEPTORS, CHOLINERGIC
  distribution of 3H-acetylcholine and 3H-nicotine, 80
  neuron stimulation, 79
  regulation of 3H-nicotine sites in mice, 80

RECEPTORS, NICOTINIC
  aversive effects of nicotine injections, 193
  binding sites, 53
  chronic tolerance, 53
  ganglionic and neuromuscular types, 88-90
  high-affinity sites, 90, 92-94
  locomotor activity, 53
  low-affinity sites, 90-91
  peripheral nervous system, 88-89
  primary and secondary binding sites, 86
  radioligand binding studies, 89-92
  tolerance, 54

REINFORCEMENT
  evaluation, 279-281
  negative, behavior modification, 193
  negative, nicotine injection, 193
  nicotine addiction, 6
  positive, continuous, intravenous nicotine, 182
  positive, intermittent, intravenous nicotine, 189, 190-191
  positive, nicotine, review, 163-166
  potential of various drugs, 305
  self-administration, 276-279
  stimulus effects, 268
  tobacco cigarettes vs. nicotine polacrilex gum, 213

REINFORCERS
  cocaine vs. nicotine, 189-190
  definition, 170
  positive, biobehavioral mechanism, dependence-producing drugs, 181-182
  psychoactive drugs, 8

REINFORCEMENT
  (See also SPONTANEOUS REMISSION)
  abstinence violation effect, 532
  age factors, 316
  alcohol and opioid dependencies, 316
  attribution theory, 525-526
  biochemical detection, 313
  correlates, 315, 317-319
  definition, 312, 518
  demographics, 520
  drug dependence severity, 315-316
  drug use, 8
  family support, 321, 324
  frequency of smoking, 521
  gender differences, 520
  high-risk factors, 519, 529-530
  long-term abstinence difficulties, 311
  measurement, 313
  negative emotions, 322-324
  peer drug use, 321-322
  prevention skills, 330-331
  psychiatric impairment, 316
  quitting history, 312, 522
  rates by drug class, 313-314
  self-efficacy, 524-525
  sensory cues, 121-123
  smoking history, 521
  social learning theory, 519
  treatment effectiveness, 315, 320-321
  treatment modalities, 312-313
  typologies, 521-522
  weight gain, risk factor, 440, 520-524
  withdrawal and dependence, 522-523
  withdrawal symptom alleviation, 205
  work and leisure activities, 322, 324

RESEARCH METHODS
  biochemical markers, 514-515
  carbon monoxide, 514
  carboxyhemoglobin, 514
  confounding design factors, 119-120
  cotinine assays, 515
  nicotine dosage control, 119
  self-reports, 515
  study design, 519-514
  suspect data, 514
RESTLESSNESS
changes during abstinence or relapse, 205
nicotine polacrilex gum, 208, 210
withdrawal symptom, 199, 201

ROLL-YOUR-OWN
prevalence, men, 1964 to 1986, 580, 582

SALIVA
nicotine secretion, 33
tobacco poisoning, 595

SATIATION
comparison with comprehensive procedure, 501-502
single and multicomponent procedures, 488, 491

SELF-ADMINISTRATION
abstinence symptoms, 310
adjunctive, schedule-induced behavior, 278-279
alcohol, 278, 281
amphetamine, 278, 281
animal research methods, 279-280
behavioral process, 168
cocaine, 278-281
compulsive use, 149
drive state, 277
drug substitution, 278
environmental pressure, 279
free sampling, 277
graduation, 277-278
human and animal studies, 276-277
human research methods, 280-281
initiation, 277
intravenous nicotine, response rates, humans, 192
morphine, 278, 281
nicotine, 278-281
pentobarbital, 278, 281
positive reinforcement, 276-277, 279
reinforcing effects, 279-280
reinitiation of drug use, 310
voluntary conditions, 279

SENSATION
environmental stimulus, conditioned reinforcers, 191
place conditioning, 284
psychological enhancement and sensory gratification, 413

SEROTONIN
interneuronal communication system, 98
pharmacological effects of nicotine, 99-100

SEX RATIO
adolescents, weight control and smoking, 438
body weight, smokers vs. nonsmokers, 415, 417, 421, 431
cessation and relapse rates, 505-508
education, 506-507
heavy vs. light smokers, 577
high school seniors, smoking prevalence, 574-576
Hispanics, smoking prevalence, 569-570
motivation to quit, 506
neuroticism and adult smoking habit, 402
smokeless tobacco use, 1970 to 1986, 580, 583
smoking cessation rates, 580, 581
smoking prevalence, 569, 572, 573, 579
social support, 508
social values and beliefs, 507
stress and smoking, 118, 508
weight gain after smoking cessation, 416, 433, 507-508

SLEEP
disturbances, nicotine polacrilex gum, 208, 210
disturbances, smokeless tobacco withdrawal symptom, 207
disturbances, withdrawal symptom, 202, 204, 205, 206

SMELL
aversion to alcohol, 280
environmental stimulus, conditioned reinforcers, 191
receptors, 58-59
tobacco grade and type, 58-59
tobacco smoke, place conditioning, 288

SMOKE CONSTITUENTS
acetaldehyde effects, 60
benzo(a)pyrene, 604
brand switching, 162
nonnicotine, tracheobronchial sensations, 168-169
SMOKE INHALATION, ANIMAL
lungs, spleen, intestine, and brain, nicotine concentrations, 84

SMOKELESS TOBACCO
(See also SNUFF)
addiction, with nicotine, 13
demographic changes, 306
nicotine dependence, 214
starter products, 265
withdrawal symptoms, 207

SMOKELESS TOBACCO USE
gum and mouth diseases and neoplasms, 213
prevalence, 1970 to 1986, 580, 583

SMOKING ANTECEDENTS
anxious, aggressive, and neurotic personality traits, 402
personality measures, 402
stress, adolescents, 400

SMOKING ARTICLES
ventilated cigarette holders, 159

SMOKING BEHAVIOR
biochemical and behavioral measures, 154
carbon monoxide intake, 154
cigarette length, 161
consistent patterns, 155
measurement techniques, 150-152
perceived functions of smoking, 307
Surgeon General's Report, 12
switching cigarette brands, 161-162
taste and smell, 58-59

SMOKING CONTROL PROGRAMS
multicomponent, smoking cessation, 501-503
Surgeon General's Report, 12

SMOKING HABIT
negative- and positive-affect regulation, 399
smoking-related disease diagnosis, 150
United States, adults, prevalence, 565-567
young adults, prevalence and consumption, 578

SMOKING SURVEYS
adolescents, 573-577
Adult Use of Tobacco Survey, 572
Behavioral Risk Factor Surveillance System, 573
Current Population Survey, 573

SMOKING SURVEYS—Contd.
Hispanic Health and Nutrition Examination Survey, 569-570
National Health Interview Surveys, 566-568, 572
self-reported smoking status, 567-568
Smoke use trends, 9

SNUFF
(See also SMOKELESS TOBACCO)
angina pectoris, 600
dipping prevalence, 1970 to 1986, 580, 583
nicotine absorption, 29-31
nicotine levels, 38
paroxysmal hypertension, 600

SOCIAL SUPPORT
buddy system, 495
gender differences, 508
global support, 527
partner support, 527-528
smoking cessation, 526-527
spouse, 406

SOCIOECONOMIC FACTORS
(See also DEMOGRAPHIC FACTORS)
body weight, smokers vs. nonsmokers, 420, 428
ethnic, class, gender differences, 505
smoking prevalence, 1985, 571
treatment and prevalence, 467

SPONTANEOUS REMISSION
(See also RELAPSE)
comparison by drug class, 255-259
contributing factors, 255-259
studies, 257-258

STATE-DEPENDENT LEARNING
abstinence vs. smoking, 393-394
definition, nicotine, humans, 181, 389
nicotine effects, 387

STATISTICAL ANALYSIS
Addiction Research Center Inventory, 271-272
discrimination procedures, 271
Morphine Benzedrine Group scale, 271-273
overlap of drug classes, 271

STIMULANTS
addiction, 247
INDEX

STIMULANTS—Contd.
addictive patterns, 282
discriminative effects, 272
nicotine, 177

STRESS
abstaining and coping, 528–529
adult cigarette consumption, 401
affect modulation, smoking and nicotine effects, 405–408
affect regulation, smoking, 395–399
consumption increases, 404
elimination of nicotine, 41
Hassles Scale, 528
hedonic systems model, negative affect, 411
initiation and consumption risk, 413–414
lateralized affective processors model, 412
low- vs. high-nicotine cigarettes, 405
management skills, 332
Navy men, smoking habit, 403–404
nicotine polacrilex gum, 405
nicotine withdrawal, conditioned responses, 408
nurses, smoking habit, 403
perceived stress, 528
perceptual and pain-endurance thresholds, nicotine effects, 410
psychophysiological reactivity, 117–122
reduction, gender differences, 508, 528
reduction, neurochemical role of nicotine, 408–409
reduction, smokers vs. nonsmokers, 407
relationship to relapse, 528–529
risk factor for adolescent smoking, 399–401
smoking and nicotine effects, 381
smoking cessation relapse, 402, 528
subjective well-being, smoking effects, 394–395

STUDENTS
high school boys, body weight and smoking, 438
high school seniors, smoking prevalence, 574–576
junior and senior high school, stress and smoking initiation, 400

SWEDEN
body weight, smokers vs. nonsmokers and ex-smokers, 428

SYMPATHETIC NERVOUS SYSTEM
arousal regulation with nicotine, 409

TAR CONTENT
sales-weighted average yield, 566
smoking maintenance, 58
tobacco taste characteristics, 58

TASTE
environmental stimulus, conditioned reinforcers, 191
first cigarette of day, 47
menthol popularity among black Americans, 510
receptors, 58
tobacco cigarettes vs. nicotine polacrilex gum, 215
tobacco grade and type, 58
tobacco smoke, place conditioning, 285

TASTE AVERSION
alcohol, 280
apomorphine vs. nicotine, 196
chlorisondomine, 196
nicotine conditioning, animals, 195–196

TAXATION
reflection of cigarette consumption, 565

TERATOGENICITY
animals, 601
humans, 601–602

THERAPY
approved drug uses, 298
deterrent, silver acetate, 485–486
replacement, 326–328
symptomatic, 328

TOBACCO CONSTITUENTS
beta-carbolines, pharmacologic effects, 60

TOBACCO SUBSTITUTES
smoke condensate, sensory effects, 169

TOLERANCE
acquired reaction, 289
acute, tachyphylaxis, 44, 47–50
animal and human studies, 251
INDEX

TOLERANCE—Contd.
behavioral, 44
behavioral and physiological responses to nicotine, 197
chronic, 44, 50–54
constitutional reaction, 290
cross-tolerance, 288, 292
dependence potential testing, 286
dose escalation, 50, 51
intoxication, 251
limits on escalation, 286–287
measures, 288
mechanisms, 288–290
nicotine addiction, 6
nicotine uptake, 8
pharmacodynamic, functional, 44
pharmacokinetic, dispositional, 44
toxic effects, 45

TOXICITY
acute, 593–596
 acute sensitivity, 45, 46
children, 598
chronic, 596
nicotine polacrilex gum, 595–596
physiological and psychological, 252

TREATMENT
(See also CESSATION OF SMOKING, METHODS; NICOTINE DELIVERY, ALTERNATE; NICOTINE POLACRILEX GUM; NICOTINE REPLACEMENT)
abstinence maintenance, 503
behavioral strategies, 329–334
blockade therapy, 328
clonidine, 328–329
goals, 325
family support, 333
leisure activity skills, 331–332
loss of control, 325
methodology, 513–516
motivation enhancement, 332–334
nicotine polacrilex gum, maintaining physical dependence, 210
overview, 465–470
peer support, 334
pharmacologic approaches, 326–329
professional contact, 333
relapse prevention skills, 330–331
relief from withdrawal symptoms, 327
replacement therapy, 326–328
stress management skills, 332
symptomatic therapy, 328

TREMOR
hand, changes during abstinence or relapse, 205
smoking effects, 392

TWINS
body weight, smokers vs. nonsmokers, 417

TYROSINE HYDROXYLASE INHIBITOR
histofluorescence studies, 100

UNITED KINGDOM
Wales, body weight, smokers vs. nonsmokers and ex-smokers, 416

URINE
acidification and cigarette consumption, 163
cotinine, 36, 37
nicotine isomethonium, 57
nicotine-N-oxide, 36, 37
pH and stress, 41
unchanged nicotine content, 33

VISION
conditioned reinforcer, nicotine delivery, 191
environmental stimulus, 191
information processing task, smoking effects, 384
peripheral vision monitoring, smoking effects, 385
place conditioning, tobacco smoke, 285
psychological enhancement and sensory gratification, 413
rapid visual information task, smoking effects, 385
vigilance tasks, nicotine tablet effects, 383
vigilance tasks, smoking effects, 383

WEST VIRGINIA
smokeless tobacco use, 1986, 581

WITHDRAWAL SYMPTOMS
(See also ABSTINENCE; CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYNDROME)
aggression, 203
anxiety, 199, 201, 204, 206, 210
behavioral and physiological sequelae, 251
biting, animals, 204–205
WITHDRAWAL SYMPTOMS—Contd.

- body temperature changes, 202
- concentration difficulty, 199, 201, 204, 205, 208, 210
- conditioned drug seeking, 310
- craving, 199, 201, 204, 208-209, 210
- depression, 201, 208-210
- electroencephalography changes, 208
- environmental and pharmacologic factors, 198
- environmental stimuli, 310
- fatigue, 201, 202, 205
- further drug intake, 8
- hearing amplitude decreases, 204
- hunger, food intake, 202, 207, 209, 210, 412-413, 434
- hypothalamic consummatory drive model, nicotine, 412-413
- identified, 198-199
- increased heart rate, 210
- irritability, impatience, 199, 201, 208, 210
- measurements and techniques, 199-200
- metabolism changes, 203, 430, 456
- negative affect reduction, nicotine, 408
- nervousness, 199, 201
- nicotine blood levels with nicotine polacrilex gum, 219
- nicotine polacrilex gum, 207, 208, 472
- opioids, 291, 292
- performance, 208
- physical complaints, 199, 201, 208
- plasma nicotine levels and symptom severity, 206-207
- rebound phenomena, 204
- respiration rate decrease, 202
- restlessness, 199, 201, 208, 210
- sleep disturbances, 202, 204, 205, 206, 207, 208
- stress, 402, 408, 528, 529

WITHDRAWAL SYMPTOMS—Contd.

- tobacco cigarettes vs. nicotine polacrilex gum, 215
- weight gain, 414, 416, 422, 423, 424, 425, 431, 438, 439-440, 523

WITHDRAWAL SYNDROME

(See also ABSTINENCE; CESSATION OF SMOKING; DEPRIVATION; WITHDRAWAL SYMPTOMS)

American Psychiatric Association, recognition, 290
- autonomic measures, 291
- behavioral, 291
- dependence potential testing, 286
- distinctive signs, 296-297
- evidence of addiction, 6, 294-295
- precipitated responses, 293
- protracted, 293
- somatomotor measures, 291
- spontaneous reactions, opioids and depressants, 292
- variability, 294-295

WOMEN

- black, smoking prevalence, 569
- body weight, smokers vs. nonsmokers, 420
- education, 506-507
- electroencephalograms of neonates from smokers, 112
- prolactin and breast feeding, smoking effects, 102
- smoking prevalence, 569
- social factors, 507-508
- stress and smoking, 400, 508
- Surgeon General's Report, 12
- treatment programs, 467
- weight control, 439, 507-508
- weight gain, 523

WORKPLACE

Surgeon General's Report, 12

YUGOSLAVIA

- body weight, smokers vs. nonsmokers and ex-smokers, 425